Colette Balaam, CEO of the Colait, shared on LinkedIn:
“We’re thrilled to share that our latest qualitative research on multiple myeloma access, funding, and treatment decision-making – capturing real-world perspectives from UK consultant hematologists – will be presented at a major international hematology congress this fall.
This study sheds light on how funding pathways, institutional capacity, and clinical trial access shape treatment decisions for patients living with multiple myeloma, and where advocacy is already driving meaningful change.
Full findings, thematic analysis, and additional insights coming soon. Stay tuned!”
Other articles about multiple myeloma on OncoDaily.